Alprox-TD is based on NexMed’s proprietary NexACT drug delivery technology, which the company has also used to develop a number of experimental medicines, including treatments for nail fungus and sexual disorders.
“This new technical development will further enhance our product’s commercialization prospects,” stated Daniel Frank, senior director of pharmaceutical operations at NexMed. “The ease of distributing a room temperature formulation of Alprox-TD, compared to a refrigerated formulation, will be of great interest and importance to potential pharmaceutical partners with whom we are currently in discussion.”
NexMed’s new regulatory strategy for Alprox-TD, meanwhile, will include the filing of a new drug application in the US and a marketing authorization application in Europe during the first half of 2007.